Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City
Elizabeth A. Garcia, Mary M K Foote, Tristan D. McPherson, Maura K. Lash, Amma N Bosompem, Alyssa Bouscaren, Justin Chan, Madeline A. DiLorenzo, Dennis Feihel, Randal C. Fowler, Vani Gandhi, Elizabeth R. Jenny-Avital, Erik Kopping, Dana Mazo, Jacob McLean, Ofole Mgbako, Mark Sayegh, Raphael Shaw, Michelle Su, Jeanne Sullivan Meissner, Jade Wang, Wendy Wen, J. Christian Winters, Cosmina B Zeana, Jason Zucker, Marcia Wong
Abstract
Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.